Lynch Syndrome, KRAS, and PIK3CA: A Distinct Molecular Landscape in Indonesian Colorectal Cancer (CRC) and What Indonesia Is Teaching the World

PathGen Diagnostik Teknologi · 2026-03-25

Research from PathGen showing that Indonesian colorectal cancer (CRC) patients possess a distinct molecular profile with significantly higher rates of oncogenic mutations—specifically 61.88% for RAS and 46.1% for PIK3CA—than Western or regional averages. Notably, 81.25% of probable Lynch syndrome cases and 76.19% of microsatellite instability (MSI) tumors harbored KRAS mutations, challenging traditional assumptions that link Lynch syndrome and MSI primarily to low KRAS mutation rates or BRAF-driven pathways. Because anti-EGFR therapies are ineffective against RAS-mutant cancers, the findings demonstrate that routine RAS testing is essential to prevent unnecessary toxicity and costs in Indonesia, making frontline immunotherapy the preferred strategy while underscoring the need for locally informed precision oncology worldwide.

What if CRC in Indonesia is not simply following global patterns, but redefining them?

Recent molecular evidence from PathGen’s research on the profiling of Indonesian colorectal cancer (CRC) patients has revealed a distinct molecular signature that challenges long-held assumptions regarding Lynch syndrome, oncogenic mutations, and established treatment paradigms. This is not merely a local observation. It serves as a global imperative for reassessing precision oncology.

What Makes Indonesian CRC Different?

Utilizing the BioColoMelt-Dx PCR-HRM Kit for the molecular detection of MSI, MLH1, BRAF, KRAS, NRAS, and PIK3CA mutations, our analysis identified exceptionally high rates of oncogenic mutations within the Indonesian cohort. RAS mutations were detected in 61.88% of cases, while 46.1% harbored PIK3CA mutations. These frequencies are markedly higher than those typically reported in Asia-Pacific (37-52%) and Western (32-49%) populations, indicating a unique molecular biology inherent to CRC in Indonesia. Furthermore, among patients classified as probable Lynch syndrome, an unexpected 81.25% harbored KRAS mutations, compared to 58.64% in non-Lynch cases (p = 0.018).

These data are consistent with previous Indonesian studies. One study identified KRAS mutations in 71.8% of serrated adenocarcinoma (SA) cases, which is significantly higher than the generally reported incidence of 40% [1]. Another study utilizing next-generation sequencing (NGS) found KRAS mutations in 63.6% of Indonesian patients with primarily advanced CRC [2]. Distinct mutations located in codons 13, 14, 34, 58, 59, and 146 were identified, diverging from the more commonly reported mutations in codons 12, 13, 61, and 146 [3–4]. A recent study in China also reported that KRAS mutations were found in 69.4% of early lesions [5–6].

Reshaping the Treatment Paradigm

Traditionally, Lynch syndrome–associated CRC is believed to be driven primarily by mismatch repair deficiency, typically exhibiting lower KRAS mutation rates. However, the Indonesian data suggest an alternative biological trajectory in which oncogenic KRAS activation is prevalent even in hereditary-like CRC.

When these local findings are integrated with the National Comprehensive Cancer Network (NCCN) guidelines, the necessity for precision oncology becomes clear. Anti-EGFR monoclonal antibodies, such as Cetuximab and Panitumumab, are only effective in tumors that are wild-type for KRAS and NRAS. In RAS-mutant tumors, these therapies are ineffective because downstream signalling remains constitutively activated despite EGFR blockade [7]. Administering anti-EGFR therapy without prior RAS testing exposes patients to unnecessary toxicity and imposes a substantial financial burden without clinical benefit. For the Indonesian healthcare system, where cost-effectiveness is paramount, routine RAS testing is a strategic necessity.

The MSI and KRAS Coexistence

Microsatellite instability (MSI) in Indonesian CRC also demonstrates a striking pattern. Contrary to traditional expectations, 76.19% of MSI tumors harbored KRAS mutations, significantly higher than the 58.91% observed in microsatellite-stable (MSS) tumors (p = 0.038). Similarly, PIK3CA mutations were present in 59.52% of MSI tumors, compared to 40.59% in MSS tumors (p = 0.027).

These findings challenge the paradigm that associates MSI primarily with BRAF-driven carcinogenesis and MSS with KRAS alterations. Instead, the Indonesian data reveal that MSI, KRAS, and PIK3CA frequently coexist. According to NCCN guidelines, MSI-H/dMMR CRC should receive first-line immune checkpoint inhibitors, such as Pembrolizumab or Nivolumab, due to superior progression-free survival compared to conventional chemotherapy. In the Indonesian context, where KRAS mutations frequently coexist with MSI, immunotherapy becomes the preferred frontline strategy, as EGFR-targeted therapy is contraindicated regardless of MSI status.

Global Implications

Most CRC guidelines are predicated on Western population data. The frequent coexistence of MSI with KRAS and PIK3CA mutations underscores the limitations of a "onesize-fits-all" approach to precision oncology. For regions with similar demographics, this study reinforces a vital global message: effective CRC management necessitates locally informed molecular profiling to ensure accurate diagnosis, appropriate therapy selection, and equitable precision medicine.

Read the LinkedIn issue